Is Core Scientific (CORZ) Stock Too Expensive After Its 12% Drop?

Core Scientific stock has given investors a rough month, with the share price under pressure while broader valuation checks suggest the company does not screen as a bargain on usual metrics. For anyone tracking mining-focused crypto infrastructure, the current setup raises questions about how much optimism is already embedded in the US$17.37 share price.

• Over the past 30 days, Core Scientific has fallen 12.1%, which points to a period where expectations have cooled after earlier gains this year.
• Future returns for the business may hinge on how efficiently it can run its mining fleet and manage energy and capital costs, since these factors can heavily influence cash generation in a volatile Bitcoin pricing backdrop.
• The stock scores 0 out of 6 on a broader set of valuation checks, which signals that Core Scientific does not look like a clear bargain based on this framework.

The issue now is whether the recent pullback has moved Core Scientific closer to a reasonable entry point or if the shares still lean expensive given the risks around its cash flows and cost base.

Scan beyond Core Scientific and compare it with 33 high quality undervalued stocks, which pair cleaner balance sheets with cash flows that may better justify their current market prices.

Is Core Scientific Getting Expensive on Sales?

P/S is often a cleaner lens for Core Scientific because profitability and free cash flow are currently under pressure, while revenue is easier to observe and compare.

On this yardstick, Core Scientific trades at roughly 12.7x sales. The broader software industry sits closer to 3.9x, and peers average about 2.2x. The fair P/S ratio implied by the model is 6.1x, which is roughly half of where the stock currently changes hands, so the market is attaching a heavy premium to each dollar of Core Scientific revenue.

That gap suggests investors are already paying up for the crypto mining footprint and potential operating improvements rather than buying a discounted top line today. Anyone evaluating Core Scientific stock through this lens is not seeing a bargain multiple, but a valuation that assumes favorable outcomes on execution and Bitcoin economics.

On the P/S metric, Core Scientific currently screens as overvalued relative to both benchmarks and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Core Scientific Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the P/S puzzle leaves off for Core Scientific and explain which assumptions on growth, profitability and earnings would need to hold for the current share price to appear meaningfully higher or lower in hindsight. Each scenario is used as a thesis about Core Scientific's business that you can track over time rather than a static fair value snapshot. These can be found on Simply Wall St's Community page for investors who want that extra layer of context.

One of the top community narratives on Core Scientific: 53% undervalued

"Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term..."

Read one of the top narratives on Core Scientific

Do you think there's more to the story for Core Scientific? Head over to our Community to see what others are saying!

The Bottom Line

Core Scientific currently looks overvalued on simple sales multiples, with the share price asking investors to pay a premium for each dollar of revenue. The broader valuation checks are weak, so the market is already baking in a constructive story on execution and Bitcoin economics rather than offering a clear discount. For you, the key question is whether Core Scientific can translate its crypto infrastructure and contracts into durable cash generation that eventually backs up this richer tag, or whether the current premium leaves little margin for error if operating progress stalls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com